Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 37.12% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 37.12% YoY) and the FY2025 annual result came in at $1.8 million, down 47.18% from the prior year.
• Non-Current Deffered Revenue declined to $1.6 million in Q1 2026 per CRBU's latest filing, from $1.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $18.2 million in Q2 2023 and bottomed at $1.6 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $4.6 million (2024), against an average of $6.9 million.
• The widest annual swing landed in 2022, when Non-Current Deffered Revenue surged 741.41%; it then plunged 74.65% in 2024.
• Tracing CRBU's Non-Current Deffered Revenue over 5 years: stood at $16.0 million in 2022, then tumbled by 61.75% to $6.1 million in 2023, then tumbled by 45.64% to $3.3 million in 2024, then sank by 47.18% to $1.8 million in 2025, then decreased by 5.94% to $1.6 million in 2026.
• Per Business Quant, the three latest CRBU Non-Current Deffered Revenue figures stand at $1.6 million (Q1 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025).

Peer Comparison